TABLE 6.

Lung function parameters and glomerular filtration rates following administration of CMS by nebulization or i.v. infusion^a

Respiratory parametersb	Effects with nebulized administration of CMS at dose of:				Effects with i.v. infusion of 150 mg of CBAc
	2 million IU		4 million IU
	Predose	Postdosed	Predose	Postdosed	Predose	Postdosed
FEV1e	2.0 ± 0.65	1.9 ± 0.65	2.0 ± 0.61	2.1 ± 0.64f	2.1 ± 0.62	2.1 ± 0.62
FVCe	3.6 ± 0.85	3.5 ± 0.94	3.9 ± 0.87	3.8 ± 0.93f	3.9 ± 0.78	3.9 ± 0.88
MIPe	155 ± 64	151 ± 44	160 ± 40	161 ± 33	148 ± 39	153 ± 36
MEPe	157 ± 56	157 ± 55	158 ± 30	166 ± 38	152 ± 29	164 ± 30
eGFRg	127 ± 18	121 ± 20h	133 ± 22	121 ± 37	145 ± 22	127 ± 31h

^aData represented as mean ± SD (n = 6).

^bFEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; MIP, minimum inspiratory pressure; MEP, maximum expiratory pressure.

^cFor lung function parameters, n = 5, as subject 2 did not undergo lung function tests since he presented with hemoptysis.

^dOne to two hours postadministration for lung function test; 12 h postadministration for eGFR.

^eNo statistically significant difference between pre- and postdose measurements for FEV₁, FVC, MIP, and MEP.

^fDue to time constraints in the lung function laboratory, n = 5, as FEV₁ and FVC could not be carried out for subject 2.

^gNo statistically significant difference was found between pre- and postdose measurements for eGFR following nebulized CMS delivery. A statistically significant difference was found between pre- and postdose measurements for eGFR following i.v. CMS delivery.

^hn = 4 for nebulized 2 million IU CMS and n = 5 for i.v. 150 mg of CBA.